Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leu

  • PDF / 1,846,816 Bytes
  • 12 Pages / 595.276 x 790.866 pts Page_size
  • 34 Downloads / 162 Views

DOWNLOAD

REPORT


ORIGINAL ARTICLE

Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all‑trans retinoic acid and chemotherapy Hideho Henzan1 · Ken Takase2 · Tomohiko Kamimura3 · Yasuo Mori4 · Goichi Yoshimoto4 · Hiromi Iwasaki2 · Koji Nagafuji5 · Ryosuke Ogawa6 · Tetsuya Eto1 · Naoyuki Uchida7 · Tomoaki Fujisaki8 · Koji Kato4 · Mariko Minami2,4 · Yoshikane Kikushige4 · Koichi Akashi4 · Toshihiro Miyamoto4   · for the Fukuoka Blood & Marrow Transplantation Group (FBMTG) Received: 10 February 2020 / Revised: 4 May 2020 / Accepted: 27 May 2020 © Japanese Society of Hematology 2020

Abstract We stratified patients with newly diagnosed acute promyelocytic leukemia (APL) according to a white blood cell (WBC) count of ≥ 3 × 109/L (high risk) or